Abstract: Nasopharyngeal carcinoma (NPC) is a highly prevalent head and neck malignancy in China, presenting significant challenges in early diagnosis. In 2019, the Expert Committee of Nasopharyngeal Cancer Biomarker, under the Tumor Biomarker Committee of China Anti⁃Cancer Association, convened a panel of multidisciplinary experts to publish the inaugural edition of the Expert consensus on the clinical application of nasopharyngeal carcinoma biomarkers, providing standardized guidance for clinical practice. With rapid advancements in novel biomarker research, this consensus has been comprehensively revised from the first edition, incorporating the latest research developments in NPC biomarkers and expert recommendations. The updates focus on supplementing clinical application evidence for novel serum biomarkers (P85⁃Ab), microbiome biomarkers, and immune microenvironment biomarkers, as well as optimizing the dynamic monitoring pathway of epstein⁃barr virus DNA and strategies for multi⁃biomarker application. This consensus aims to further enhance the precision of NPC screening, efficacy evaluation, and prognosis prediction through the systematic integration of cutting⁃edge research findings.

Key words: Nasopharyngeal carcinoma； Cancer biomarker； Epstein?Barr virus； Clinical application, Expert consensus